EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Tetherin Restricts SARS-CoV-2 despite the Presence of Multiple Viral Antagonists

Elena Hagelauer iD, Rishikesh Lotke, Dorota Kmiec, Dan Hu, Mirjam Hohner, Sophie Stopper iD, Rayhane Nchioua, Frank Kirchhoff iD, Daniel Sauter, Michael Schindler iD

Viruses · 30.11.2023 · 15 (12) · 2364

DOI: 10.3390/v15122364 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Viruses, online erschienen am 30.11.2023. Verfasst von Elena Hagelauer und 9 weiteren Autor:innen. Beteiligte Einrichtung: Institute for Medical Virology and Epidemiology of Viral Diseases, University Hospital Tübingen, 72076 Tübingen, Germany. Hauptthemen laut MEDLINE: Bone Marrow Stromal Antigen 2, COVID-19, Severe acute respiratory syndrome-related coronavirus. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: European Research Council, COVID-19 research grant of the Federal Ministry of Education and Research, Heisenberg Program of the German Research Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Coronavirus infection induces interferon-stimulated genes, one of which encodes Tetherin, a transmembrane protein inhibiting the release of various enveloped viruses from infected cells. Previous studies revealed that SARS-CoV encodes two Tetherin antagonists: the Spike protein (S), inducing lysosomal degradation of Tetherin, and ORF7a, altering its glycosylation. Similarly, SARS-CoV-2 has also been shown to use ORF7a and Spike to enhance virion release in the presence of Tetherin. Here, we directly compare the abilities and mechanisms of these two viral proteins to counteract Tetherin. Therefore, cell surface and total Tetherin levels upon ORF7a or S expression were investigated using flow cytometry and Western blot analysis. SARS-CoV and SARS-CoV-2 S only marginally reduced Tetherin cell surface levels in a cell type-dependent manner. In HEK293T cells, under conditions of high exogenous Tetherin expression, SARS-CoV-2 S and ORF7a reduced total cellular Tetherin levels much more efficiently than the respective counterparts derived from SARS-CoV. Nevertheless, ORF7a from both species was able to alter Tetherin glycosylation. The ability to decrease total protein levels of Tetherin was conserved among S proteins from different SARS-CoV-2 variants (α, γ, δ, ο). While SARS-CoV-2 S and ORF7a both colocalized with Tetherin, only ORF7a directly interacted with the restriction factor in a two-hybrid assay. Despite the presence of multiple Tetherin antagonists, SARS-CoV-2 replication in Caco-2 cells was further enhanced upon Tetherin knockout. Altogether, our data show that endogenous Tetherin restricts SARS-CoV-2 replication and that the antiviral activity of Tetherin is only partially counteracted by viral antagonists with differential and complementary modes of action.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Bone Marrow Stromal Antigen 2COVID-19Severe acute respiratory syndrome-related coronavirusHumansCaco-2 CellsGPI-Linked ProteinsHEK293 CellsSARS-CoV-2

Stichwörter der Autor:innen

BST2ORF7aSARS-CoVSARS-CoV-2SpikeTetherinrestriction factor

Substanzen

Bone Marrow Stromal Antigen 2GPI-Linked Proteins

Autor:innen und Institutionen

  • Institute for Medical Virology and Epidemiology of Viral Diseases, University Hospital Tübingen, 72076 Tübingen, Germany.
  • Institute of Molecular Virology, Ulm University Medical Center, 89081 Ulm, Germany.

ORCID-Profile: Elena Hagelauer, Sophie Stopper, Frank Kirchhoff, Michael Schindler

Förderung

  • European Research Council
  • COVID-19 research grant of the Federal Ministry of Education and Research
  • Heisenberg Program of the German Research Foundation
  • DFG
  • ERC
  • Ulm University, Else Kröner Fresenius Stiftung
  • European Union’s Horizon 2020 Marie Sklodowska-Curie programme
  • University of Tübingen

Zitieren

APA

Hagelauer, E., Lotke, R., Kmiec, D., Hu, D., Hohner, M., Stopper, S., Nchioua, R., Kirchhoff, F., Sauter, D., & Schindler, M. (2023). Tetherin Restricts SARS-CoV-2 despite the Presence of Multiple Viral Antagonists. Viruses, 15(12), 2364. https://doi.org/10.3390/v15122364

Vancouver

Hagelauer E, Lotke R, Kmiec D, Hu D, Hohner M, Stopper S, et al. Tetherin Restricts SARS-CoV-2 despite the Presence of Multiple Viral Antagonists. Viruses. 2023;15(12):2364. doi:10.3390/v15122364

BibTeX
@article{Hagelauer2023,
  author = {Hagelauer, Elena and Lotke, Rishikesh and Kmiec, Dorota and Hu, Dan and Hohner, Mirjam and Stopper, Sophie and Nchioua, Rayhane and Kirchhoff, Frank and Sauter, Daniel and Schindler, Michael},
  title = {Tetherin Restricts SARS-CoV-2 despite the Presence of Multiple Viral Antagonists},
  journal = {Viruses},
  year = {2023},
  volume = {15},
  number = {12},
  pages = {2364},
  doi = {10.3390/v15122364}
}
Kostenlos starten →